Search the Newsreel

LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summary

Lisata Therapeutics, Inc. reported a Q2 2026 revenue of $0 and a diluted loss per share of ($0.32), with net loss narrowing to ($2.93M). The company is pursuing strategic alternatives due to near-term funding uncertainty, including a significant workforce reduction and a lawsuit following …

Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment

Lisata Therapeutics has announced a significant workforce reduction of approximately 72%, aiming to cut operating expenses and explore strategic options. This move, approved on August 3, 2026, is expected to incur $1.2 million in severance costs. Concurrently, the company filed a lawsuit against Kuva …

Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce

Lisata Therapeutics has filed a lawsuit against Kuva Labs Inc. and its subsidiary in Delaware, seeking damages and a $2 million termination fee following the termination of their merger agreement. Concurrently, Lisata has reduced its workforce by approximately 72% to cut operating expenses and …

Lisata Therapeutics (LSTA) Pursues Legal Action After Merger Termination, Faces Valuation Challenges

Lisata Therapeutics (LSTA) has initiated legal proceedings against Kuva Labs and its subsidiary following the termination of their merger agreement, seeking a $2 million termination fee and damages for shareholders. Concurrently, Lisata is exploring strategic alternatives, including potential sales or liquidation, and has significantly …

Lisata Therapeutics, Inc. (LSTA) Files 8-K Announcing Retention Bonus Agreement With James Nisco

Lisata Therapeutics, Inc. (LSTA) has filed an 8-K report detailing a major workforce reduction of approximately 72% as part of a cost-cutting initiative to explore strategic options. The company also announced legal action against Kuva Labs Inc. for an alleged breach of a merger …

Lisata Therapeutics moves forward with legal action following Kuva merger termination

Lisata Therapeutics has filed a lawsuit against Kuva Labs in the Delaware Court of Chancery following the termination of their merger agreement, alleging a breach of contract and seeking damages and a $2 million termination fee. The company is also actively evaluating strategic alternatives …

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

Lisata Therapeutics announced the termination of its merger agreement with Kuva Labs Inc., prompting the company to file a lawsuit against Kuva for breach of contract and seeking a $2 million termination fee. In response to the termination and to conserve cash while exploring …

LSTA|Lisata Therapeutics Inc|Price:1.010|Chg%:-0.020

This article provides a comprehensive stock analysis of Lisata Therapeutics Inc (LSTA), highlighting its relatively healthy fundamentals, significant growth potential, and high institutional ownership. Despite a recent weak market performance, the company shows strong underlying metrics. The stock is currently deemed fairly valued within …

Lisata Therapeutics Inc (LSTA) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Lisata Therapeutics Inc (LSTA), assigning it a TradingKey financial score of 6.89, ranking it 188 out of 385 in the Biotechnology & Medical Research industry. While the company's financial status is described as robust, its operating efficiency …

Kuva Labs (LSTA) ends Lisata cash-and-CVR tender offer after financing shortfall

Kuva Labs (via its subsidiary Kuva Acquisition Corp.) has terminated its tender offer to acquire Lisata Therapeutics (LSTA) due to an inability to secure the necessary financing. The offer, which included $4.00 cash per share plus one contingent value right (CVR) for up to …

PT Indosat Tbk (PTITF) (H1 2026) Earnings Call Highlights: Robust Growth and Strategic ...

This article first appeared on GuruFocus. Revenue: Increased by 13.1% year-on-year to IDR30.7 trillion in the first half of 2026. EBITDA: Grew by 13.6% year-on-year, with a margin increase of 0.2% to 47.6%. Net Profit: Normalized net profit rose by 49.2% year-on-year. ARPU: Customer …

Lisata Therapeutics, Inc. Revenue Breakdown – MUN:8NE

Lisata Therapeutics, Inc. (MUN:8NE) generated 85.14K EUR in revenue last year. The top-performing segment was Certepetide, contributing 144.74K EUR, significantly down from 965.98K EUR the previous year. The United States was the largest regional contributor, also at 144.74K EUR, compared to 965.98K EUR in …

Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Lisata Therapeutics Inc (LSTA), including business segments and regional contributions. However, it explicitly states that the relevant data have not been disclosed by the company yet. Therefore, no detailed financial information regarding revenue …

Lisata Therapeutics Inc (LSTA) Valuation: PE, PB & Fair Value Analysis

Lisata Therapeutics Inc (LSTA) has a current valuation score of 6.17, placing it 351st out of 386 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -0.90, which is significantly below its recent high and above its recent low. The company …

Lisata Therapeutics Inc (LSTA) Cash Flow

This article provides a detailed cash flow statement for Lisata Therapeutics Inc (LSTA), including operating, investing, and financing cash flows presented quarterly and annually. It includes historical data dating back to FY2012Q1 and defines key cash flow metrics. The data reveals various financial movements, …

Lisata Therapeutics (LSTA) Plunges 21%: Key Levels to Watch - Zero Gamma Level

Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal

Lisata Therapeutics announced the termination of its acquisition agreement with Kuva Labs, effective July 25, 2026. Following this news, the company's shares experienced a significant decline of over 26% during premarket trading. The deal's termination indicates a change in strategic direction or unfulfilled conditions …

Lisata Therapeutics Terminates Merger Agreement With Kuva Labs On July 24, Says SEC Filing

Lisata Therapeutics announced the termination of its merger agreement with Kuva Labs on July 24, according to a recent SEC filing. The news was reported by Reuters and indicates a change in the strategic plans for both companies.

Lisata Therapeutics Inc (LSTA) Institutional Confidence

Lisata Therapeutics Inc (LSTA) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. This score reflects a 10.92% institutional shareholding proportion, which increased by 34.03% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.46% of …

Lisata Therapeutics Stock Falls After Hours: Here's Why

Lisata Therapeutics (LSTA) shares fell in after-hours trading after the company revealed that the buyer, Kuva Acquisition Corp., was unable to fund its tender offer to acquire Lisata. Approximately 66.8% of Lisata's outstanding common stock had been tendered, meeting the minimum condition for the …

Lisata Therapeutics (LSTA) says Kuva tender meets conditions but financing not yet secured

Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – LSE:0HS8

This article provides financial information for Lisata Therapeutics, Inc. (LSE:0HS8), specifically focusing on its Enterprise Value to EBIT forward metric. It appears to be a stub or an entry on a financial data platform like TradingView, with details about its market on the London …

[8-K] LISATA THERAPEUTICS, INC. Reports Material Event

Lisata Therapeutics, Inc. (NASDAQ: LSTA) filed an 8-K report announcing an amendment to its Agreement and Plan of Merger with Kuva Labs Inc. and Kuva Acquisition Corp. The amendment extends the contractual "Outside Date" for the merger from July 17, 2026, to July 21, …

Lisata Therapeutics, Kuva Labs Amend Merger Agreement to Extend Outside Date to July 21

Lisata Therapeutics and Kuva Labs have amended their merger agreement, extending the "Outside Date" from July 17, 2026, to July 21, 2026. This extension allows for additional time to finalize the pending tender offer and merger steps. The amendment aims to ensure all remaining …

Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer

Lisata Therapeutics 1Q 2026: Revenue $0 EPS $(0.50) — 10-Q Summary

Indosat distributes IDR 3.57 trillion dividend, implying 5.2% yield

Lisata investors offered $5 cash now, $1 more if certepetide gets filed

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

ISAT profit slips 7.5% by September 2025 as cellular business slows

Cellular data revenue declines, Indosat profit drops 14.6% in H1 2025

Indosat dividend at IDR 83.3 per share, massive drop post stock split

Indosat plans major business expansion into AI, IoT, and defense tech